(Q36115014)

12 August 2017

Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia (English)

1 reference

cost-effectiveness analysis

12 August 2017

1 reference

1 reference

1 reference

Barosi G

1

1 reference

12 August 2017

Marchetti M

series ordinal

2

1 reference

12 August 2017

Liberato NL

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 September 1998

1 reference

British Journal of Cancer

12 August 2017

1 reference

12 August 2017

78

1 reference

12 August 2017

781-787

1 reference

12 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1998.579

12 August 2017

0 references

cites work

Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062982

Cost of allogeneic and autologous blood transfusion in Canada. Canadian Cost of Transfusion Study Group

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062982

Transfusion requirements, risks, and costs for patients with malignancy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062982

Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062982

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062982

Post-transfusion hepatitis: impact of non-A, non-B hepatitis surrogate tests. Canadian Post-Transfusion Hepatitis Prevention Study Group

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062982

Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062982

Recombinant human erythropoietin in the treatment of the anaemia of cancer

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062982

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062982

The Declining Risk of Post-Transfusion Hepatitis C Virus Infection

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062982

The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062982

Non-A, non-B post-transfusion hepatitis. Looking back in the second decade

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062982

The cost effectiveness of preoperative autologous blood donations

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062982

Prediction of response to erythropoietin treatment in chronic anemia of cancer.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062982

Clinical outcomes after transfusion-associated hepatitis C.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062982

Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062982

A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer

23 September 2018

1 reference

12 December 2020

Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer

1 reference

12 December 2020

Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response

1 reference

12 December 2020

Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study)

1 reference

12 December 2020

Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia

1 reference

12 December 2020

Non-A, non-B posttransfusion hepatitis--a decade later

1 reference

12 December 2020

The risk of transfusion-transmitted infection

1 reference

12 December 2020

The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada

1 reference

12 December 2020

The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement

1 reference

12 December 2020

Erythropoietin for anaemia in cancer patients

1 reference

12 December 2020

Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo

1 reference

12 December 2020

Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies

1 reference

12 December 2020

A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1998.579

1 reference

12 August 2017

1 reference

12 August 2017

1 reference